Incidence and prevalence of venous thromboembolism in Norway 2010–2017

Brodin, Ellen; Schultze, Anna; Shepherd, Leah; Lambrelli, Dimitra; Ulvestad, Maria; Ramagopalan, Sreeram; Halvorsen, Sigrun

doi:10.1016/j.thromres.2020.07.011

Cited by 15 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have established a trend toward higher incidence of venous thromboembolism in both the general population 27,28 and among cancer patients. [12][13][14] Our results extend these observations by showing a simultaneous decline in mortality following cancer-associated venous thromboembolism.…”

Section: Discussionmentioning

confidence: 97%

Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study

Ording

Skjøth

Søgaard

et al. 2021

The American Journal of Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study

Ording

Skjøth

Søgaard

et al. 2021

The American Journal of Medicine

View full text Add to dashboard Cite

“…Genome-wide data from GBMI and 23andMe data were not available and therefore excluded from combined analyses. We estimated the heterogeneity associated with each variant using Cochran’s Q test and the corresponding I 2 statistic. We assessed the genomic inflation with the lambda genomic control.…”

Section: Methodsmentioning

confidence: 99%

Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors

Thibord

Klarin

Brody

et al. 2022

Preprint

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a complex disease with environmental and genetic determinants. We present new cross-ancestry meta-analyzed genome-wide association study (GWAS) results from 30 studies, with replication of novel loci and their characterization through in silico genomic interrogations. In our initial genetic discovery effort that included 55,330 participants with VTE (47,822 European, 6,320 African, and 1,188 Hispanic ancestry), we identified 48 novel associations of which 34 replicated after correction for multiple testing. In our combined discovery-replication analysis (81,669 VTE participants) and ancestry-stratified meta-analyses (European, African and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein QTL Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 novel GWAS loci provided insights to biological pathways contributing to VTE, indicating that some loci may contribute to VTE through well-characterized coagulation pathways while others provide new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. In summary, these findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of antithrombosis treatments with reduced risk of bleeds.

show abstract

“…The incidence of pulmonary embolism (PE) has been steadily increasing over the past 2 decades, at least in high‐income countries. 1 , 2 , 3 , 4 , 5 An improvement in life expectancy, particularly among patients with conditions predisposing to venous thromboembolism (VTE), such as cancer, chronic obstructive pulmonary disease, and autoimmune diseases, may partly explain this finding in most countries. Other factors explaining this trend include the broader adoption of validated diagnostic algorithms, greater awareness, a lower threshold of clinical suspicion, and the standard use of computed tomographic pulmonary angiography.…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of pulmonary embolism (PE) has been steadily increasing over the past 2 decades, at least in high‐income countries 1‐5 . An improvement in life expectancy, particularly among patients with conditions predisposing to venous thromboembolism (VTE), such as cancer, chronic obstructive pulmonary disease, and autoimmune diseases, may partly explain this finding in most countries.…”

Section: Introductionmentioning

confidence: 99%

Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries

Valerio

Gallo

Turatti

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Introduction Pulmonary embolism (PE) has not been accounted for as a cause of death contributing to cause‐specific mortality in global reports. Methods We analyzed global PE‐related mortality by focusing on the latest year available for each member state in the World Health Organization (WHO) mortality database, which provides age‐sex–specific aggregated mortality data transmitted by national authorities for each underlying cause of death. PE‐related deaths were defined by International Classification of Diseases, Tenth Revision codes for acute PE or nonfatal manifestations of venous thromboembolism (VTE). The 2001 WHO standard population served for standardization. Results We obtained data from 123 countries covering a total population of 2 602 561 422. Overall, 50 (40.6%) were European, 39 (31.7%) American, 13 (10.6%) Eastern Mediterranean, 13 (10.6%) Western Pacific, 3 (2.4%) Southeast Asian, and 2 (1.6%) African. Of 116 countries classifiable according to population income, 57 (49.1%) were high income, 42 (36.2%) upper‐middle income, 14 (12.1%) lower‐middle income, and 3 (2.6%) low income. A total of 18 726 382 deaths were recorded, of which 86 930 (0.46%) were attributed to PE. PE‐related mortality rate increased with age in most countries. The reporting of PE‐related deaths was heterogeneous, with an age‐standardized mortality rate ranging from 0 to 24 deaths per 100 000 population‐years. Income status only partially explained this heterogeneity. Conclusions Reporting of PE‐related mortality in official national vital registration was characterized by extreme heterogeneity across countries. These findings mandate enhanced efforts toward systematic and uniform coverage of PE‐related mortality and provides a case for full recognition of PE and VTE as a primary cause of death.

show abstract

Incidence and prevalence of venous thromboembolism in Norway 2010–2017

Cited by 15 publications

References 10 publications

Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study

Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study

Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors

Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries

Contact Info

Product

Resources

About